Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostaglandins and macrophages

A W Ford-Hutchinson, M V Doig

    Agents and Actions. Supplements
    |January 1, 1979
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.

    The Journal of pharmacology and experimental therapeutics·2001
    Same author

    The human prostanoid DP receptor stimulates mucin secretion in LS174T cells.

    British journal of pharmacology·2001
    Same author

    A random rapid equilibrium mechanism for leukotriene C4 synthase.

    Advances in experimental medicine and biology·2000
    Same author

    A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor.

    European journal of pharmacology·1999
    Same author

    Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.

    The Journal of pharmacology and experimental therapeutics·1999
    Same author

    The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.

    Bioorganic & medicinal chemistry letters·1999
    Same journal

    Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways.

    Agents and actions. Supplements·1998
    Same journal

    Immunomodulation of Crohn's disease by interleukin-10.

    Agents and actions. Supplements·1998
    Same journal

    Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis.

    Agents and actions. Supplements·1998
    Same journal

    Symposium new drugs for inflammatory, allergic and immunologic disease.

    Agents and actions. Supplements·1998
    Same journal

    The complexity of the B7-CD28/CTLA-4 costimulatory pathway.

    Agents and actions. Supplements·1998
    Same journal

    A role for inflammatory cytokines in the productive activation of antigen-specific CD4+ T-cells.

    Agents and actions. Supplements·1998
    See all related articles